Sampling Strategies for Tissue Microarrays to Evaluate Biomarkers in Ovarian Cancer

被引:11
|
作者
Permuth-Wey, Jenny
Boulware, David
Valkov, Nikola
Livingston, Sandra
Nicosia, Santo
Lee, Ji-Hyun
Sutphen, Rebecca
Schildkraut, Joellen [2 ]
Narod, Steven [3 ]
Parker, Alex [4 ]
Coppola, Domenico
Sellers, Thomas
Pal, Tuya [1 ]
机构
[1] Univ S Florida, H Lee Moffitt Canc Ctr, Dept Canc Epidemiol & Genet, MRC CANCONT, Tampa, FL 33612 USA
[2] Duke Univ, Durham, NC USA
[3] Womens Coll Hosp, Ctr Res Womens Hlth, Toronto, ON M5S 1B2, Canada
[4] Mayo Clin, Coll Med, Jacksonville, FL 32224 USA
关键词
NONPOLYPOSIS COLORECTAL-CANCER; MICROSATELLITE INSTABILITY; MISMATCH-REPAIR; TUMOR HETEROGENEITY; BREAST-CANCER; RISK; IMMUNOHISTOCHEMISTRY; VALIDATION; CARCINOMA; HMLH1;
D O I
10.1158/1055-9965.EPI-08-0713
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: Tissue microarrays (TMA) enable rapid analysis of biomarkers in large-scale studies involving archival tumor specimens, however, their utility in heterogeneous tumors such as ovarian cancer is limited. Methods: In this study, immunohistochemical analysis was done on TMAs comprised of epithelial ovarian cancer (EOC) to estimate the prevalence of loss of expression of three mismatch repair proteins. TMAs were initially created using cores sampled from the center of donor tissue blocks from 59 EOC cases. Full sections were subsequently created and levels of expression were compared between tissues sampled from the central portion versus the periphery. Followup analyses were done by obtaining cores from the periphery of up to five additional donor blocks per case. A linear mixed model for each protein was used to investigate differences between results from the initial and follow-up blocks. Results: In the original TMAs created using centrally sampled cores, loss of mismatch repair expression was noted in 17 (29%) of the 59 cases. By comparison, analyses from peripherally sampled cores revealed loss of expression in only 6 of these 17 cases. For each protein, significant differences (P < 0.05) were detected between results from the initial donor block and the majority of the follow-up blocks. Conclusions: Our investigations, based on EOC, suggest that sampling variability in protein expression may result when TMAs are used. Thus, at least for EOC, it is important to preferentially sample from the periphery of tumor blocks where exposure to tissue fixatives is optimal. (Cancer Epidemiol Biomarkers Prev 2009;18(1):28-34)
引用
收藏
页码:28 / 34
页数:7
相关论文
共 50 条
  • [1] OSov: An Interactive Web Server to Evaluate Prognostic Biomarkers for Ovarian Cancer
    Yan, Zhongyi
    Wang, Qiang
    Zhao, Susu
    Xie, Longxiang
    Zhang, Lu
    Han, Yali
    Zhang, Baokun
    Li, Huimin
    Guo, Xiangqian
    BIOLOGY-BASEL, 2022, 11 (01):
  • [2] Tissue microarrays for testing basal biomarkers in familial breast cancer cases
    Dufloth, Rozany Mucha
    Matos, Irina
    Schmitt, Fernando
    Zeferino, Luiz Carlos
    SAO PAULO MEDICAL JOURNAL, 2007, 125 (04): : 226 - 230
  • [3] Prevalence of Occult Ovarian Cancer and Metastatic Breast Cancer in Ovarian Ablation Specimens of Patients With Hormone Receptor-Positive Breast Cancer: Implications for Tissue Sampling Strategies, Early Ovarian Cancer Detection and Resource Utilization
    Walia, Anjali
    Ladwig, Nicholas R.
    Mak, Julie S.
    Rabban, Joseph T.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 2025, 44 (02) : 174 - 181
  • [4] Circulating and Tissue microRNAs as Biomarkers for Ovarian Cancer Prognosis
    Parizadeh, Seyed Mostafa
    Jafarzadeh-Esfehani, Reza
    Ghandehari, Maryam
    Hasan-zadeh, Malihe
    Parizadeh, Seyed Mohammad Reza
    Hassanian, Seyed Mandi
    Rezaei-Kalat, Afsaneh
    Aghabozorgi, Amirsaeed Sabeti
    Rahimi-Kakhki, Rana
    Zargaran, Bita
    Ferns, Gordon A.
    Avan, Amir
    CURRENT DRUG TARGETS, 2019, 20 (14) : 1447 - 1460
  • [5] Tissue microarray is suitable for scientific biomarkers studies in endometrial cancer
    Visser, Nicole C. M.
    van der Wurff, Anneke A. M.
    Pijnenborg, Johanna M. A.
    Massuger, Leon F. A. G.
    Bulten, Johan
    Nagtegaal, Iris D.
    VIRCHOWS ARCHIV, 2018, 472 (03) : 407 - 413
  • [6] Tissue Microarrays in Non-Small-Cell Lung Cancer: Reliability of Immunohistochemically-Determined Biomarkers
    Pohl, Mette
    Olsen, Karen Ege
    Holst, Rene
    Ditzel, Henrik Jorn
    Hansen, Olfred
    CLINICAL LUNG CANCER, 2014, 15 (03) : 222 - +
  • [7] Recent technical strategies to identify diagnostic biomarkers for ovarian cancer
    Ye, Bin
    Gagnon, Audrey
    Mok, Samuel C.
    EXPERT REVIEW OF PROTEOMICS, 2007, 4 (01) : 121 - 131
  • [8] Tissue Microarrays are Reliable Tools for the Clinicopathological Characterization of Lung Cancer Tissue
    Schmidt, Lars Henning
    Biesterfeld, Stefan
    Kuemmel, Andreas
    Faldum, Andreas
    Sebastian, Martin
    Taube, Christian
    Buhl, Roland
    Wiewrodt, Rainer
    ANTICANCER RESEARCH, 2009, 29 (01) : 201 - 209
  • [9] Biomarkers for Predicting Complete Debulking in Ovarian Cancer: Lessons to Be Learned
    Fago-Olsen, Carsten Lindberg
    Ottesen, Bent
    Christensen, Ib Jarle
    Hogdall, Estrid
    Lundvall, Lene
    Nedergaard, Lotte
    Engelholm, Svend-Aage
    Antonsen, Sofie Leisby
    Lydolph, Magnus
    Hogdall, Claus
    ANTICANCER RESEARCH, 2014, 34 (02) : 679 - 682
  • [10] Analysis of gene amplification and prognostic markers in ovarian cancer using comparative genomic hybridization for microarrays and immunohistochemical analysis for tissue microarrays
    Mayr, Doris
    Kanitz, Veronika
    Anderegg, Birgit
    Luthardt, Beate
    Engel, Jutta
    Loehrs, Udo
    Amann, Gudrun
    Diebold, Joachim
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2006, 126 (01) : 101 - 109